MedTrace Logo

Oral Tranexamic Acid After Total Knee Arthroplasty

NCT06894719 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2026-02-23

No results posted yet for this study

Summary

This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively.

Hypothesis:

Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.

Conditions

  • Total Knee Arthroplasty

Interventions

DRUG

tranexamic acid Oral-Short Arm

1.95g Tranexamic acid daily for post op days 1 to 3

DRUG

tranexamic acid Oral-Long Arm

1.95g tranexamic acid daily post op days 1-7

DRUG

Control group placebo

Placebo for 3 days post-op

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Bailey Terhune, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2026-12-01
Completion
2027-05-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06894719 on ClinicalTrials.gov